Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables - Other (2019 - 2022)

Historic Receivables - Other for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Q4 2022 value amounting to $700000.0.

  • 4D Molecular Therapeutics' Receivables - Other changed 0.0% to $700000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $700000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $700000.0 for FY2022, which is 0.0% changed from last year.
  • As of Q4 2022, 4D Molecular Therapeutics' Receivables - Other stood at $700000.0, which was down 0.0% from $700000.0 recorded in Q4 2021.
  • 4D Molecular Therapeutics' 5-year Receivables - Other high stood at $700000.0 for Q4 2021, and its period low was $149000.0 during Q4 2019.
  • Over the past 3 years, 4D Molecular Therapeutics' median Receivables - Other value was $630500.0 (recorded in 2021), while the average stood at $527500.0.
  • Over the last 5 years, 4D Molecular Therapeutics' Receivables - Other had its largest YoY gain of 0.0% in 2022, and its largest YoY loss of 0.0% in 2022.
  • Quarter analysis of 3 years shows 4D Molecular Therapeutics' Receivables - Other stood at $149000.0 in 2019, then surged by 369.8% to $700000.0 in 2021, then changed by 0.0% to $700000.0 in 2022.
  • Its Receivables - Other was $700000.0 in Q4 2022, compared to $700000.0 in Q4 2021 and $561000.0 in Q1 2021.